Glenmark Pharmaceuticals Limited (Glenmark), An Innovation-Driven Global Pharmaceutical Company, Became The First To Launch Teneligliptin (20Mg) + Dapagliflozin (5Mg/10Mg) Fixed Dose Combination (Fdc) For The Treatment Of Adult Patients With Type 2 Diabetes, Especially The Ones With Comorbidities. Marketed Under The Brand Name Zita D; It Contains Teneligliptin (20Mg) + Dapagliflozin (5 Mg/10 Mg), And Must Be Taken Once Daily Under Prescription To Improve Glycaemic Control & Prevent Complications In Adult Patients With Type 2 Diabetes, Especially The Ones With Comorbidities. On The Launch, Alok Malik, Evp & Business Head - India Formulations, Glenmark Pharmaceuticals, Said,
